T. Nojima

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance

K. Fujihara, H. Sone, K. Kaku, 2020, Diabetic medicine : a journal of the British Diabetic Association.

Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin.

K. Fujihara, H. Sone, Shiro Tanaka, 2019, The Journal of clinical endocrinology and metabolism.

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Y. Eguchi, A. Nakajima, R. Loomba, 2021, Alimentary pharmacology & therapeutics.

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination

S. Yamashita, H. Arai, E. Araki, 2019, International journal of molecular sciences.

Predictors of the response of HbA1c and body weight after SGLT2 inhibition.

K. Fujihara, H. Sone, K. Kaku, 2017, Diabetes & metabolism.

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

S. Yamashita, H. Arai, E. Araki, 2021, Cardiovascular Diabetology.